KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2025)

Ginkgo Bioworks Holdings' Free Cash Flow history spans 6 years, with the latest figure at -$47.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 15.07% year-over-year to -$47.7 million; the TTM value through Dec 2025 reached -$178.7 million, up 53.23%, while the annual FY2025 figure was -$178.7 million, 53.23% up from the prior year.
  • Free Cash Flow reached -$47.7 million in Q4 2025 per DNA's latest filing, down from -$31.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$10.7 million in Q3 2021 to a low of -$170.7 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$75.6 million, with a median of -$65.7 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: tumbled 368.63% in 2023, then surged 73.35% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$170.7 million in 2021, then rose by 23.72% to -$130.2 million in 2022, then surged by 52.93% to -$61.3 million in 2023, then rose by 8.38% to -$56.1 million in 2024, then increased by 15.07% to -$47.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Free Cash Flow are -$47.7 million (Q4 2025), -$31.6 million (Q3 2025), and -$40.3 million (Q2 2025).